Suppr超能文献

E3 泛素连接酶 Cbl-b 对免疫反应的调节。

Regulation of immune responses by E3 ubiquitin ligase Cbl-b.

机构信息

Department of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan, PR China.

School of Biological Sciences, University of Western Australia, Perth, Australia.

出版信息

Cell Immunol. 2019 Jun;340:103878. doi: 10.1016/j.cellimm.2018.11.002. Epub 2018 Nov 7.

Abstract

Casitas B lymphoma-b (Cbl-b), a RING finger E3 ubiquitin ligase, has been identified as a critical regulator of adaptive immune responses. Cbl-b is essential for establishing the threshold for T cell activation and regulating peripheral T cell tolerance through various mechanisms. Intriguingly, recent studies indicate that Cbl-b also modulates innate immune responses, and plays a key role in host defense to pathogens and anti-tumor immunity. These studies suggest that targeting Cbl-b may represent a potential therapeutic strategy for the management of human immune-related disorders such as autoimmune diseases, infections, tumors, and allergic airway inflammation. In this review, we summarize the latest developments regarding the roles of Cbl-b in innate and adaptive immunity, and immune-mediated diseases.

摘要

卡斯蒂亚斯 B 淋巴瘤-b(Cbl-b),一种 RING 指 E3 泛素连接酶,已被确定为适应性免疫反应的关键调节因子。Cbl-b 对于建立 T 细胞激活的阈值以及通过各种机制调节外周 T 细胞耐受至关重要。有趣的是,最近的研究表明 Cbl-b 还调节先天免疫反应,并在宿主防御病原体和抗肿瘤免疫中发挥关键作用。这些研究表明,靶向 Cbl-b 可能代表管理人类免疫相关疾病(如自身免疫性疾病、感染、肿瘤和过敏性气道炎症)的一种潜在治疗策略。在这篇综述中,我们总结了 Cbl-b 在先天和适应性免疫以及免疫介导的疾病中的最新作用。

相似文献

1
Regulation of immune responses by E3 ubiquitin ligase Cbl-b.
Cell Immunol. 2019 Jun;340:103878. doi: 10.1016/j.cellimm.2018.11.002. Epub 2018 Nov 7.
2
E3 ubiquitin ligase Cbl-b in innate and adaptive immunity.
Cell Cycle. 2014;13(12):1875-84. doi: 10.4161/cc.29213. Epub 2014 May 14.
3
Essential role of E3 ubiquitin ligase activity in Cbl-b-regulated T cell functions.
J Immunol. 2011 Feb 15;186(4):2138-47. doi: 10.4049/jimmunol.1003390. Epub 2011 Jan 19.
4
Differential control of CD28-regulated in vivo immunity by the E3 ligase Cbl-b.
J Immunol. 2005 Feb 1;174(3):1472-8. doi: 10.4049/jimmunol.174.3.1472.
6
Regulation of peripheral T cell tolerance by the E3 ubiquitin ligase Cbl-b.
Semin Immunol. 2007 Jun;19(3):206-14. doi: 10.1016/j.smim.2007.02.004. Epub 2007 Mar 27.
7
E3 ubiquitin ligase Casitas B lineage lymphoma-b and its potential therapeutic implications for immunotherapy.
Clin Exp Immunol. 2021 Apr;204(1):14-31. doi: 10.1111/cei.13560. Epub 2021 Jan 10.
8
E3 ubiquitin ligase Cbl-b negatively regulates C-type lectin receptor-mediated antifungal innate immunity.
J Exp Med. 2016 Jul 25;213(8):1555-70. doi: 10.1084/jem.20151932. Epub 2016 Jul 18.
10
The ubiquitin E3 ligase Cbl-b in T cells tolerance and tumor immunity.
Cell Cycle. 2007 Oct 15;6(20):2478-85. doi: 10.4161/cc.6.20.4797. Epub 2007 Jul 26.

引用本文的文献

1
The role of ubiquitination and deubiquitination in urological tumours.
Front Pharmacol. 2025 Jul 23;16:1532878. doi: 10.3389/fphar.2025.1532878. eCollection 2025.
3
Natural Killer Cell Immune Checkpoints and Their Therapeutic Targeting in Cancer Treatment.
Research (Wash D C). 2025 Jun 3;8:0723. doi: 10.34133/research.0723. eCollection 2025.
4
Cbl-b inhibitor NX-1607 activates MAPK/ERK signaling pathway and enhances T-cell activation.
J Immunother Cancer. 2025 May 30;13(5):e011180. doi: 10.1136/jitc-2024-011180.
5
Primary disorders of polyubiquitination: Dual roles in autoinflammation and immunodeficiency.
J Exp Med. 2025 May 5;222(5). doi: 10.1084/jem.20241047. Epub 2025 Apr 15.
6
K27-linked RORγt ubiquitination by Nedd4 potentiates Th17-mediated autoimmunity.
J Biomed Sci. 2025 Feb 19;32(1):26. doi: 10.1186/s12929-025-01120-2.
8
Potential Therapeutic Benefit of the Selective Inhibitors of Casitas B Cell Lymphoma-b (CBL-B) in Cancer Immunotherapy.
ACS Med Chem Lett. 2024 Nov 19;15(12):2085-2087. doi: 10.1021/acsmedchemlett.4c00533. eCollection 2024 Dec 12.
9
Update on type 2 immunity.
J Allergy Clin Immunol. 2025 Feb;155(2):327-335. doi: 10.1016/j.jaci.2024.11.003. Epub 2024 Nov 9.
10
Ex vivo modeling of precision immuno-oncology responses in lung cancer.
Sci Adv. 2024 Nov;10(44):eadq6830. doi: 10.1126/sciadv.adq6830. Epub 2024 Oct 30.

本文引用的文献

1
CBLB Constrains Inactivated Vaccine-Induced CD8 T Cell Responses and Immunity against Lethal Fungal Pneumonia.
J Immunol. 2018 Sep 15;201(6):1717-1726. doi: 10.4049/jimmunol.1701241. Epub 2018 Jul 27.
2
Cbl Ubiquitin Ligases Control B Cell Exit from the Germinal-Center Reaction.
Immunity. 2018 Mar 20;48(3):530-541.e6. doi: 10.1016/j.immuni.2018.03.006.
3
Regulation of C-Type Lectin Receptor-Mediated Antifungal Immunity.
Front Immunol. 2018 Feb 1;9:123. doi: 10.3389/fimmu.2018.00123. eCollection 2018.
4
Glycogen Synthase Kinase-3 Modulates Cbl-b and Constrains T Cell Activation.
J Immunol. 2017 Dec 15;199(12):4056-4065. doi: 10.4049/jimmunol.1600396. Epub 2017 Nov 6.
5
RING-Between-RING E3 Ligases: Emerging Themes amid the Variations.
J Mol Biol. 2017 Nov 10;429(22):3363-3375. doi: 10.1016/j.jmb.2017.08.008. Epub 2017 Aug 19.
6
Cblb-deficient T cells are less susceptible to PD-L1-mediated inhibition.
Oncotarget. 2017 Jun 27;8(26):41841-41853. doi: 10.18632/oncotarget.18360.
7
Interleukin-17A Promotes CD8+ T Cell Cytotoxicity To Facilitate West Nile Virus Clearance.
J Virol. 2016 Dec 16;91(1). doi: 10.1128/JVI.01529-16. Print 2017 Jan 1.
8
E3 ubiquitin ligase Cbl-b negatively regulates C-type lectin receptor-mediated antifungal innate immunity.
J Exp Med. 2016 Jul 25;213(8):1555-70. doi: 10.1084/jem.20151932. Epub 2016 Jul 18.
9
Inhibition of CBLB protects from lethal Candida albicans sepsis.
Nat Med. 2016 Aug;22(8):915-23. doi: 10.1038/nm.4134. Epub 2016 Jul 18.
10
Targeting CBLB as a potential therapeutic approach for disseminated candidiasis.
Nat Med. 2016 Aug;22(8):906-14. doi: 10.1038/nm.4141. Epub 2016 Jul 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验